In conclusion, we found that CDK4/6 inhibitors reduce mutant p53 expression, and subsequently suppress tumor cell proliferation in both RB-proficient and RB-deficient triple-negative breast cancer (TNBC) cells. Here, TP53 is linked to triple-negative breast carcinoma.